Literature DB >> 22685342

The serotonin 2C receptor antagonist SB 242084 exhibits abuse-related effects typical of stimulants in squirrel monkeys.

Daniel F Manvich1, Heather L Kimmel, Debra A Cooper, Leonard L Howell.   

Abstract

Antagonists of the serotonin (5-hydroxytryptamine; 5-HT) type 2C receptor (5-HT(2C)R) are being considered as potential pharmacotherapeutics for various affective disorders, but evidence suggests that these compounds enhance the effects of cocaine and related psychostimulants in rodents. However, the effects of selective 5-HT(2C)R antagonists have not been evaluated in nonhuman primates. The present studies used operant-behavioral and in vivo microdialysis techniques to assess the impact of 5-HT(2C)R antagonism on the behavioral and neurochemical effects of cocaine in squirrel monkeys. In subjects trained to lever-press on a fixed-interval schedule of stimulus termination, pretreatment with the highly selective 5-HT(2C)R antagonist 6-chloro-2,3-dihydro-5-methyl-N-[6-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl]-1H-indole-1-carboxyamide dihydrochloride (SB 242084) (vehicle, 0.01-0.1 mg/kg) produced behavioral-stimulant effects alone and interacted with cocaine in an apparently additive manner. In monkeys trained to self-administer intravenous cocaine according to a second-order schedule of drug delivery, SB 242084 (vehicle, 0.03-0.1 mg/kg) modulated cocaine-induced reinstatement of previously extinguished responding and maintained self-administration behavior when substituted for cocaine availability. These studies are the first to assess the direct reinforcing effects of a 5-HT(2C)R-selective antagonist in any species. Finally, in vivo microdialysis studies revealed that pretreatment with SB 242084 (0.1 mg/kg) modulated cocaine-induced dopamine increases within the nucleus accumbens, but not the caudate nucleus, of awake subjects. Taken together, the results suggest that SB 242084 exhibits a behavioral profile that is qualitatively similar to other psychostimulants, although its efficacy is modest compared with cocaine. The observed interactions with cocaine and the substitution for cocaine self-administration may be indicative of some degree of abuse potential in humans.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22685342      PMCID: PMC3422522          DOI: 10.1124/jpet.112.195156

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  43 in total

Review 1.  The medical benefit of 5-HT research.

Authors:  Brian J Jones; Thomas P Blackburn
Journal:  Pharmacol Biochem Behav       Date:  2002-04       Impact factor: 3.533

2.  Regional distribution and cellular localization of 5-HT2C receptor mRNA in monkey brain: comparison with [3H]mesulergine binding sites and choline acetyltransferase mRNA.

Authors:  J F López-Giménez; G Mengod; J M Palacios; M T Vilaró
Journal:  Synapse       Date:  2001-10       Impact factor: 2.562

3.  Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding.

Authors:  Paul J Fletcher; Andrew J Grottick; Guy A Higgins
Journal:  Neuropsychopharmacology       Date:  2002-10       Impact factor: 7.853

Review 4.  5-HT2C receptor modulators: a patent survey.

Authors:  Junwon Lee; Myung Eun Jung; Jinhwa Lee
Journal:  Expert Opin Ther Pat       Date:  2010-09-17       Impact factor: 6.674

Review 5.  Molecular, pharmacological and functional diversity of 5-HT receptors.

Authors:  Daniel Hoyer; Jason P Hannon; Graeme R Martin
Journal:  Pharmacol Biochem Behav       Date:  2002-04       Impact factor: 3.533

6.  Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study.

Authors:  G Di Giovanni; V Di Matteo; M Di Mascio; E Esposito
Journal:  Synapse       Date:  2000-01       Impact factor: 2.562

7.  Enhanced locomotor, reinforcing, and neurochemical effects of cocaine in serotonin 5-hydroxytryptamine 2C receptor mutant mice.

Authors:  Beatriz A Rocha; Evan H Goulding; Laura E O'Dell; Andy N Mead; Nicole G Coufal; Loren H Parsons; Laurence H Tecott
Journal:  J Neurosci       Date:  2002-11-15       Impact factor: 6.167

8.  Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat.

Authors:  A Gobert; J M Rivet; F Lejeune; A Newman-Tancredi; A Adhumeau-Auclair; J P Nicolas; L Cistarelli; C Melon; M J Millan
Journal:  Synapse       Date:  2000-06-01       Impact factor: 2.562

9.  In vivo evidence that 5-HT2C receptor antagonist but not agonist modulates cocaine-induced dopamine outflow in the rat nucleus accumbens and striatum.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère; Grégory Porras; Umberto Spampinato
Journal:  Neuropsychopharmacology       Date:  2004-02       Impact factor: 7.853

Review 10.  Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review.

Authors:  Meera Vaswani; Farzana Kadar Linda; Subramanyam Ramesh
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2003-02       Impact factor: 5.067

View more
  15 in total

1.  Attenuation of cocaine-induced reinstatement of drug seeking in squirrel monkeys by direct and indirect activation of 5-HT2C receptors.

Authors:  Daniela Rüedi-Bettschen; Roger D Spealman; Donna M Platt
Journal:  Psychopharmacology (Berl)       Date:  2015-04-17       Impact factor: 4.530

Review 2.  A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Authors:  Jose M Palacios; Angel Pazos; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

3.  Role of 5-HT₂C receptors in effects of monoamine releasers on intracranial self-stimulation in rats.

Authors:  Clayton T Bauer; Matthew L Banks; Bruce E Blough; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2015-06-05       Impact factor: 4.530

4.  Lorcaserin decreases the reinforcing effects of heroin, but not food, in rhesus monkeys.

Authors:  Stephen J Kohut; Jack Bergman
Journal:  Eur J Pharmacol       Date:  2018-09-27       Impact factor: 4.432

5.  Lorcaserin Suppresses Oxycodone Self-Administration and Relapse Vulnerability in Rats.

Authors:  Harshini Neelakantan; Erica D Holliday; Robert G Fox; Sonja J Stutz; Sandra D Comer; Margaret Haney; Noelle C Anastasio; F Gerard Moeller; Kathryn A Cunningham
Journal:  ACS Chem Neurosci       Date:  2017-02-13       Impact factor: 4.418

Review 6.  Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction.

Authors:  Kathryn A Cunningham; Noelle C Anastasio
Journal:  Neuropharmacology       Date:  2013-07-11       Impact factor: 5.250

7.  Effects of the serotonin 2C receptor agonist WAY163909 on the abuse-related effects and mesolimbic dopamine neurochemistry induced by abused stimulants in rhesus monkeys.

Authors:  Laís F Berro; Maylen Perez Diaz; Eric Maltbie; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2017-06-05       Impact factor: 4.530

8.  Pharmacological Modulation of 5-HT2C Receptor Activity Produces Bidirectional Changes in Locomotor Activity, Responding for a Conditioned Reinforcer, and Mesolimbic DA Release in C57BL/6 Mice.

Authors:  Caleb J Browne; Xiaodong Ji; Guy A Higgins; Paul J Fletcher; Colin Harvey-Lewis
Journal:  Neuropsychopharmacology       Date:  2017-06-13       Impact factor: 7.853

9.  Effects of pharmacologic dopamine β-hydroxylase inhibition on cocaine-induced reinstatement and dopamine neurochemistry in squirrel monkeys.

Authors:  Debra A Cooper; Heather L Kimmel; Daniel F Manvich; Karl T Schmidt; David Weinshenker; Leonard L Howell
Journal:  J Pharmacol Exp Ther       Date:  2014-05-09       Impact factor: 4.030

Review 10.  The behavioral pharmacology and therapeutic potential of lorcaserin for substance use disorders.

Authors:  Gregory T Collins; Lisa R Gerak; Charles P France
Journal:  Neuropharmacology       Date:  2017-12-12       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.